A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

December 5, 2035

Study Completion Date

December 5, 2035

Conditions
Fibrodysplasia Ossificans Progressiva
Trial Locations (5)

19104

NOT_YET_RECRUITING

The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine, Philadelphia

94103

NOT_YET_RECRUITING

The Regents of the University of California, San Francisco

Unknown

NOT_YET_RECRUITING

Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton

NOT_YET_RECRUITING

Bone Research and Education Centre, Oakville

RECRUITING

University Health Network (UHN) - Toronto General, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY